drugset / Trial / NCT07131059
MRD-positive AML Clinical Study
RandomizedFactorialOpen-labelTreatment
Summary
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Timeline
- Start
- 2024-05-11
- Primary completion
- 2026-05-10
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avapritinib | Small molecule | 200 mg | — |
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Daunorubicin | Small molecule | 45 mg/m2 | — |
| Subject | Gilteritinib | Small molecule | 120 mg | — |
| Subject | HHT | Unknown | 2 mg/m2 | — |
| Subject | Idarubicin | Small molecule | 10 mg/m2 | — |
| Subject | Ivosidenib | Small molecule | 500 mg | — |
| Subject | MTZ | Unknown | 8 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Subject | Venetoclax | Small molecule | 600 mg | — |